Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
复制标题
血清胶质纤维酸性蛋白：视神经脊髓炎光谱障碍的生物标志物。
DOI：
10.1002/ana.26067
复制
发表时间：
2021-05
影响因子：
11.2
通讯作者：
N-MOmentum scientific group and the N-MOmentum study investigators
中科院分区：
文献类型：
--
作者：
Aktas O;Smith MA;Rees WA;Bennett JL;She D;Katz E;Cree BAC;N-MOmentum scientific group and the N-MOmentum study investigators
用于监测视神经脊髓炎频谱障碍（NMOSD）疾病活动性、发作严重程度或治疗效果的血液检测尚未得到发展。本研究探讨了血清胶质纤维酸性蛋白（sGFAP）浓度与NMOSD活性之间的关系，并评估了依胆单抗治疗的影响。N - MOmentum是一项前瞻性、多中心、双盲、安慰剂对照、随机临床试验，研究对象为成年NMOSD患者。通过单分子阵列（SIMOA）测量了来自215名N - MOmentum参与者（92%为水通道蛋白4免疫球蛋白G血清阳性）和对照样本（来自健康供体和复发-缓解型多发性硬化症患者）的1260个系列和攻击相关样本中的sGFAP水平。在基线时，62名参与者（29%）表现出高sGFAP浓度（≥170 pg/ml，比健康供体平均浓度高≥2个标准差），并且比基线浓度较低的参与者更有可能经历确诊发作（风险比[95%置信区间]，3.09 [1.6-6.1],p = 0.001）。发作1周内中位（四分位间距[IQR]）浓度升高（基线：168.4,IQR = 128.9-449.7 pg/ml；发作：2160.1,IQR = 302.7 - 9455.0 pg/ml, p = 0.0015），且与发作严重程度相关（与基线相比中位倍数变化[FC]，轻微发作：1.06,IQR = 0.9-7.4；严重发作：34.32,IQR = 8.7-107.5, p = 0.023）。这种与发作相关的sGFAP增加主要发生在安慰剂组（FC: 20.2, IQR = 4.4-98.3, p = 0.001），而在伊比利单抗组（FC: 1.1, IQR = 0.8-24.6, p = 0.05）中未观察到。基线sGFAP升高的5名参与者（28%）报告神经系统症状导致未确定的发作评估。血清GFAP可作为NMOSD活性、发作风险和治疗效果的生物标志物。Ann neurol 2021；89:895 - 910
Blood tests to monitor disease activity, attack severity, or treatment impact in neuromyelitis optica spectrum disorder (NMOSD) have not been developed. This study investigated the relationship between serum glial fibrillary acidic protein (sGFAP) concentration and NMOSD activity and assessed the impact of inebilizumab treatment. N‐MOmentum was a prospective, multicenter, double‐blind, placebo‐controlled, randomized clinical trial in adults with NMOSD. sGFAP levels were measured by single‐molecule arrays (SIMOA) in 1,260 serial and attack‐related samples from 215 N‐MOmentum participants (92% aquaporin 4‐immunoglobulin G‐seropositive) and in control samples (from healthy donors and patients with relapsing–remitting multiple sclerosis). At baseline, 62 participants (29%) exhibited high sGFAP concentrations (≥170 pg/ml; ≥2 standard deviations above healthy donor mean concentration) and were more likely to experience an adjudicated attack than participants with lower baseline concentrations (hazard ratio [95% confidence interval], 3.09 [1.6–6.1], p = 0.001). Median (interquartile range [IQR]) concentrations increased within 1 week of an attack (baseline: 168.4, IQR = 128.9–449.7 pg/ml; attack: 2,160.1, IQR = 302.7–9,455.0 pg/ml, p = 0.0015) and correlated with attack severity (median fold change from baseline [FC], minor attacks: 1.06, IQR = 0.9–7.4; major attacks: 34.32, IQR = 8.7–107.5, p = 0.023). This attack‐related increase in sGFAP occurred primarily in placebo‐treated participants (FC: 20.2, IQR = 4.4–98.3, p = 0.001) and was not observed in inebilizumab‐treated participants (FC: 1.1, IQR = 0.8–24.6, p > 0.05). Five participants (28%) with elevated baseline sGFAP reported neurological symptoms leading to nonadjudicated attack assessments. Serum GFAP may serve as a biomarker of NMOSD activity, attack risk, and treatment effects. ANN NEUROL 2021;89:895–910
登录
查看更多内容
DOI：
10.1111/bpa.12099
发表时间：
2014-01
期刊：
Brain pathology (Zurich, Switzerland)
影响因子：
--
作者：
Lucchinetti CF;Guo Y;Popescu BF;Fujihara K;Itoyama Y;Misu T
通讯作者：
Misu T
影响因子：
5.1
作者：
Jeong, I. H.;Choi, J. Y.;Kim, H. J.
通讯作者：
Kim, H. J.
影响因子：
11.2
作者：
Bennett, Jeffrey L.;Lam, Chiwah;Kalluri, Sudhakar Reddy;Saikali, Philippe;Bautista, Katherine;Dupree, Cecily;Glogowska, Magdalena;Case, David;Antel, Jack P.;Owens, Gregory P.;Gilden, Don;Nessler, Stefan;Stadelmann, Christine;Hemmer, Bernhard
通讯作者：
Hemmer, Bernhard
影响因子：
6.2
作者：
Papa, Linda;Lewis, Lawrence M.;Falk, Jay L.;Zhang, Zhiqun;Silvestri, Salvatore;Giordano, Philip;Brophy, Gretchen M.;Demery, Jason A.;Dixit, Neha K.;Ferguson, Ian;Liu, Ming Cheng;Mo, Jixiang;Akinyi, Linnet;Schmid, Kara;Mondello, Stefania;Robertson, Claudia S.;Tortella, Frank C.;Hayes, Ronald L.;Wang, Kevin K. W.
通讯作者：
Wang, Kevin K. W.
影响因子：
4.6
作者：
Abdelhak A;Huss A;Kassubek J;Tumani H;Otto M
通讯作者：
Otto M